Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Low Pyridoxine levels are associated with Status Epilepticus
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG) Posters (7:00 AM-5:00 PM)
099

This study aims to evaluate pyridoxine levels in patients with status epilepticus (SE), medication-resistant epilepsy, and psychogenic non-epileptic seizures (PNES)

SE affects approximately 50 000 – 60 000 new cases annually in the USA. Benzodiazepine is the initial treatment for SE, but one-third of the patients don't respond to benzodiazepines. Pyridoxine's active metabolite pyridoxal 5'-phosphate (P5P) is an essential factor in the process of decarboxylation of glutamine into Gamma-Aminobutyric Acid (GABA). Decrease concentrations of GABA can increase the risk of seizures. Seizures associated with pyridoxine deficiency are usually seen in the pediatric population. A retrospective study showed that 94% of the SE patients admitted to the NICU had low pyridoxine levels. No other study had replicate the latter findings. We aim to evaluate the levels of pyridoxine in patients with SE admitted to the NICU and compared those with levels in patients with medication-resistant epilepsy and patients without epilepsy.

This was a retrospective study performed at the University of North Carolina and the University of Florida. From 8/2019 to 8/2020, a total of 74 records from patients admitted to the NICU with the diagnosis of SE and to the epilepsy monitoring unit with the diagnosis of medication-resistant epilepsy or PNES were reviewed. Pyridoxine levels, demographics, and antiepileptic drug use were obtained. Median pyridoxine levels between groups were compared using the Test of Median and Kruskal-Wallis test due to heterogeneity of variance.

Medication-resistant epilepsy, PNES, and SE group had 27, 27, and 20 patients, respectively. Patients in the SE group had statistically significant lower levels of pyridoxine compared to patients in medication-resistant epilepsy and PNES groups (p < .001)

 
This study's results agree with prior published data and raise the possibility that low levels of pyridoxine are associated with benzodiazepines resistant seizures and progression to SE.
Authors/Disclosures
Clio A. Rubinos, MD, MSCR (University of North Carolina)
PRESENTER 		Dr. Rubinos has nothing to disclose.
Maria J. Bruzzone, MD, FÂ鶹´«Ã½Ó³»­ (University of Florida) Dr. Bruzzone has nothing to disclose.